REVIEW ARTICLE

Mouse models for gastric cancer: Matching models to biological questions

Ashleigh R Poh,*,† Robert J J O'Donoghue,‡ Matthias Ernst‡ and Tracy L Putoczki*,†

*Department of Medical Biology, University of Melbourne, †The Walter and Eliza Hall Institute of Medical Research, and ‡School of Cancer Medicine, La Trobe University, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia

Correspondence

Tracy Putoczki, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Vic. 3052, Australia. Email: tracy.putoczki@wehi.edu.au

Matthias Ernst, Olivia Newton-John Cancer Research Institute, Melbourne, Vic. 3084, Australia. Email: matthias.ernst@onjcri.org.au

Abstract

Gastric cancer is the third leading cause of cancer-related mortality worldwide. This is in part due to the asymptomatic nature of the disease, which often results in late-stage diagnosis, at which point there are limited treatment options. Even when treated successfully, gastric cancer patients have a high risk of tumor recurrence and acquired drug resistance. It is vital to gain a better understanding of the molecular mechanisms underlying gastric cancer pathogenesis to facilitate the design of new-targeted therapies that may improve patient survival. A number of chemically and genetically engineered mouse models of gastric cancer have provided significant insight into the contribution of genetic and environmental factors to disease onset and progression. This review outlines the strengths and limitations of current mouse models of gastric cancer and their relevance to the pre-clinical development of new therapeutics.

Introduction

Gastric cancer (GC) is the third leading cause of cancer mortality worldwide and affects approximately 500 000 individuals per year.[1] With the exception of Japan, most GC patients are diagnosed at advanced stages of the disease because of the lack of screening available for early detection.[2] Conventional treatments include surgery, chemotherapy, and radiation therapy; however, recurrence occurs in 50% of patients with a 5-year survival rate of approximately 20%.[3] Thus, early detection and monitoring of tumor responses to treatment are central to improving patient survival, while a deeper understanding of tumor-specific molecular targets is necessary to facilitate the development of novel and more effective therapeutics.

Chemical-induced and genetically engineered mouse models to induce random and targeted genetic mutations, respectively, have revolutionized our understanding of how genes, diet, infection, and carcinogens affect GC. Likewise, these models have provided an invaluable platform for drug discovery and validation. However, to fully exploit these models, an in-depth understanding of their tumor histopathology, molecular signatures, and the molecular networks driving the disease is important to ensure that there is an optimal match between the questions investigated and the models used for this purpose. Here, we endeavor to provide an updated description of the most commonly used GC models together with a discussion of their strengths and limitations.

Classification of GC subtypes

Gastric adenocarcinomas may be subdivided into two main histological groups according to the Lauren classification.[4] However, due to the high level of molecular heterogeneity in GC, there has been an emerging interest in further classifying GC based on patterns of molecular alterations and their correlation with disease progression and prognosis.[5,6]

Lauren classification of GC. The Lauren classification of GC was first proposed in 1965 and comprises the well-differentiated intestinal and the poorly differentiated diffused types. These subtypes differ not only in their morphology but also in terms of epidemiology, pathology, and genetic profiles. Intestinal-type GC is often initiated by *Helicobacter pylori* infection, which induces chronic gastritis and atrophy (Fig. 1).[7] Atrophy is characterized by the loss of specialized glandular tissue including the oxyntic glands with parietal cells, which modulate growth and differentiation of gastric progenitor cells.[8] In addition to the loss of important differentiation signals, a reduction

Figure 1 Pathogenesis of intestinal-type and diffuse-type gastric cancer. Intestinal-type gastric cancer (top half of diagram) develops through a series of well-characterized events, whereby *Helicobacter pylori* infection promotes the differentiation of the normal gastric mucosa to chronic gastritis, which then progresses to atrophic gastritis. This may eventually result in the formation of dysplastic lesions and intestinal-type gastric carcinoma. In contrast, the molecular mechanisms underpinning diffuse-type gastric carcinoma (bottom half of diagram) are less well defined, but are commonly associated with mutations or loss of E-cadherin. *Figure adapted from Yuasa (2003).*

in parietal cells also leads to a decrease in gastric acid secretion and achlorhydria. Consequently, bacterial overgrowth can occur, which promotes inflammation and other pathophysiological changes.[7] Indeed, gastrin-deficient mice, which have achlorhydric stomachs, are characterized by bacterial overgrowth and chronic atrophic gastritis that progresses to GC.[9] Likewise, *Helicobacter felis*-infected wild-type mice also develop achlorhydria, atrophy, and gastric tumors.[10]

As a consequence of chronic inflammation and glandular regeneration, metaplasia often occurs in intestinal-type GC. At least two distinct subtypes of metaplasia have been identified, namely, intestinal-type and spasmolytic polypeptide-expressing metaplasia (SPEM).[11] Intestinal-type metaplasia is characterized by an increase in goblet-like cells and the expression of mucin (MUC)-2 and trefoil factor (TFF)3, while SPEM is identified by the presence of TFF2 and MUC-6 expressing cells that histologically resemble cells of the Brunner's glands.[11] Interestingly, while the relationship between *H. pylori* infection, atrophy, and intestinal metaplasia is well established, a causal relationship between intestinal metaplasia and neoplastic transformation is somewhat more tenuous.[12] Indeed, SPEM is more strongly associated with GC progression and is therefore thought to be a precursor to the development of cancerous lesions.[13,14] Intestinal-type adenocarcinomas exhibit well-defined glandular structures with features such as multiple lumens, reduced stroma, and enlarged nuclei, and these adenocarcinomas are typically surrounded by a dense population of inflammatory immune cell infiltrates.[4,15] The metaplasia–neoplasia–carcinoma sequence is driven by additional mutations in genes, including *TP53*,[16] *APC*,[17] *RB1*,[18] and *TGFβ*,[19] which collectively control cellular survival and proliferation. The role of these genes in the neoplastic transformation of the gastric mucosa has been expertly reviewed by others.[15,20]

Compared with intestinal-type GC, the carcinogenic pathway driving the development of diffuse-type GC is less well

characterized. Diffuse adenocarcinomas appear as solitary clusters with a poorly differentiated and disorganized epithelial structure. The epithelial cells within these clusters are often rich in mucous-containing vacuoles that displace the nucleus to the periphery to form "signet-ring" cells, a characteristic of malignancy.[2] Although diffuse adenocarcinomas can be initiated by *H. pylori* infection, they are more commonly associated with defects in the cell-adhesion protein E-cadherin (Fig. 1), because mutation, deletion, and methylation of the corresponding *CDH1* gene is frequently observed in human disease.[4,21] E-cadherin plays a key role in epithelial integrity, and loss of E-cadherin expression is associated with disruption of cell–cell junctions and impairment of cell adhesiveness.[22] Furthermore, impaired E-cadherin activity has also been associated with increased cell growth and invasion of tissues adjacent to epithelial cancer cells, indicating a tumor suppressive role of *CDH1*.[23,24] Because of defects in adhesion, diffuse-type adenocarcinomas exhibit a higher frequency of invasion and metastasis compared with the intestinal subtype and are therefore considered to be more aggressive.[25]

Molecular classification of distinct GC subtypes.

While the Lauren classification has been useful for evaluating GC epidemiology and etiology, this morphological approach for classifying gastric tumors offers only limited clinical utility and does not predict response to available treatments. Thus, recent studies have used gene expression profiling and the availability of somatic genome-wide information to identify several distinct molecular subtypes over and above the Lauren classification (Fig. 2).[5,6] For instance, the Asian Cancer Research Group (ACRG) profiled 251 primary gastric tumors in terms of gene expression and gene copy number and combined this information with targeted gene sequencing to define four distinct GC molecular subtypes that were

ACRG GC subtypes

Mesenchymal-like (EMT)	**Microsatellite-unstable (MSI)**	**TP53-active**	**TP53-inactive**
- Predominantly diffuse type histology	- Hypermutated intestinal-type histology	- Intermediate prognosis and recurrence compared to EMT / MSI	- Intermediate prognosis and recurrence compared to EMT / MSI

- Worst prognosis with highest recurrence	- Most tumors present in the antrum	- High frequency of EBV infection	- Frequently mutated genes:
			  - P53
			  - CSKN1A
			  - MDM2

- Diagnosed at an earlier age	- Best prognosis with low recurrence	- Frequently mutated genes:
		  - APC
		  - ARID1A
		  - KRAS
		  - PIK3CA
		  - SMAD4	

- Loss of CDH1 with lower mutation events compared to other groups	- Frequently mutated genes:
	  - KRAS
	  - PI3K/PTEN-mTOR pathway
	  - ALK
	  - ARID1A
	  - Loss of MLH1		

TCGA GC subtypes

Genomically stable	**Microsatellite-unstable (MSI)**	**EBV positive**	**Chromosome-unstable**
- Diffuse histology	- Elevated rates of mutation and hypermethylation	- Most tumors present in the gastric fundus or body	- Intestinal histology
- High frequency of CDH1, ARID1A and RHOA mutation	- MLH1 silencing	- CDKN2A silencing	- Elevated frequency in the gastro-esophageal junction/cardia
- CLDN18-ARHAP fusion	- Mitotic pathways	- Recurrent PI3KA, ARID1A and BCOR mutations	- High frequency of TP53 mutation
- Cell adhesion	- Diagnosed at a relatively older age	- Frequent DNA hyper-methylation	- RTK-RAS activation
- Diagnosed at an earlier age		- JAK2 and PD-L1/L2 amplification	
		- Immune cell signalling	

Figure 2 Molecular characterization of gastric cancer subtypes. Comprehensive molecular characterization of gastric tumors has identified four main subtypes associated with distinct patterns of genetic alterations, disease progression, and clinical prognosis. The four subtypes identified by the Asian Cancer Research Group (top half of diagram) include the mesenchymal-like type (EMT), microsatellite-unstable (MSI), and tumor protein 53 (TP53)-active and TP53-inactive subtypes. The four subtypes defined by the The Cancer Genome Atlas (bottom half of diagram) include tumors positive for Epstein–Barr virus, microsatellite unstable tumors, genomically stable tumors, and tumors with chromosomal instability.

associated with distinct tumor recurrence and clinical prognosis. These subtypes include the mesenchymal-like type (EMT), microsatellite-unstable (MSI) groups, alongside the tumor protein 53 (TP53)-active and TP53-inactive subtypes (Fig. 2).[6] The EMT subtype is observed in a significantly younger subset of patients than any of the other subtypes, where the majority of patients (>80%) are diagnosed with diffuse-type tumors at stage III/IV and have a high frequency of recurrence (~63%). Moreover, while tumors in the EMT group are often characterized by loss of *CDH1*, overall, they have a lower number of mutation events when compared with the other groups.[6] In contrast, MSI tumors exhibit intestinal-type features and predominantly occur in the antral region of the stomach (75%). These tumors are often hypermutated and carry mutations in genes of the PI3K-PTEN-mTOR pathway (42%), as well as in *ARID1A* (44.2%), *KRAS* (23.3%), or *ALK* (16.3%). MSI tumors are typically diagnosed at an early stage (I/II) and have the best prognosis with lowest recurrence.[6] Lastly, the TP53-active and TP53-inactive groups exhibit an intermediate prognosis and recurrence compared with EMT and MSI subtypes. Interestingly, TP53-active tumors are also associated with a highest probability of Epstein–Barr virus infection. On the other hand, the TP53-inactive subtype has a high prevalence of TP53 mutation (60%) but exhibit low mutations in *CSKN1A* and *MDM2*, while TP53-active tumors exhibit a higher prevalence of mutations in *APC*, *ARID1A*, *KRAS*, *PIK3CA*, and *SMAD4*.[6]

A complementing assessment of 295 primary gastric adenocarcinomas by The Cancer Genome Atlas (TCGA) project also identified four distinct subtypes (Fig. 2). Again, an Epstein–Barr virus positive group was identified and exhibited recurrent *PIK3CA* mutation, DNA hyper-methylation, and amplification of *JAK2* and *PD-L1/L2*. The MSI tumors in the TGCA dataset also showed elevated mutation rates in genes involved in oncogenic signaling pathways. However, this project also identified genomically stable tumors, which are enriched for the diffuse histologic variant, and tumors with chromosomal instability that exhibit aneuploidy and amplification of receptor tyrosine kinases.[5] Interestingly, comparison of ACRG and TCGA datasets revealed a number of similarities, including the enrichment of TCGA genomically stable tumors in ACRG EMT subtypes and TCGA EBV positive groups in ACRG TP53-active subtypes, respectively.[5,6] However, a number of differences were also observed, such as the presence of TCGA tumors classified as chromosomal or genomically unstable in all ACRG subtypes. Furthermore, no equivalent subtypes that corresponded to the ACRG TP53-active and TP53-inactive groups were identified in the TCGA cohorts.[5,6] Thus, while molecular characterization studies are crucial for laying the groundwork towards the development of personalized medicine, an overall consensus remains to be established to more definitely classify clinically relevant subtypes.

While these genetic subtypes most likely help to stratify patients to new targeted therapeutics, they have not been fully replicated by mouse models. Accordingly, most of the mouse models described in the succeeding discussion have been evaluated most extensively based on the histological appearance of their cancer lesions, with only some having been assessed on the basis of similar gene expression pattern between histologically similar tumors in mice and humans.

MNU-induced gastric carcinogenesis

Prior to the classification of *H. pylori* infection as a type I carcinogen, chemical agents were used to induce GC in mice. The best characterized model of chemically induced GC involves administration of N-methyl-N-nitrosourea (MNU), an N-nitroso compound generated by anaerobic gut bacteria following ingestion of nitrates and nitrites. Normally MNU is supplemented in drinking water, and its tumorigenic efficacy depends on concentration rather than total intake.[26] Treatment of mice with MNU at 120 ppm during 5 alternating weeks promotes cancer development in a large number of genetic backgrounds (Table 1),[27] and this concentration is therefore recommended in most standard protocols. When used in conjunction with a high-salt diet, a known risk factor for GC, MNU-dependent mutagenesis significantly increases the frequency of tumor development.[28] MNU-induced tumors occur predominantly in the gastric antrum and mostly comprise well-differentiated to moderately differentiated adenocarcinomas with a large stromal cell component.[27]

The MNU model has revealed a number of signaling pathways and transcription factors involved in gastric tumorigenesis, including p53,[29] NF-κB,[30] mitogen-activated protein kinase (MAPK),[31] COX2,[28,32] β-catenin,[32] RUNX3,[33] E-cadherin,[34] and KLF-4.[35] Although the precise mechanism underpinning MNU-induced carcinogenesis remains unclear, chromatin remodeling as a result of amino acid modification in histone proteins,[36] and altered expression of the gastric tumor suppressor *Tff1* has been observed.[37] Because histone methylation and epigenetic silencing of the promoter for *TFF1* is also frequently detected in human GC, it has been proposed that MNU may mediate tumor development through a series of epigenetic modifications to the TFF1 promoter.

Helicobacter infection models

Helicobacter pylori are gram-negative, spiral-shaped bacteria that thrive in the acidic environment of the gastric mucosa.[38] Infection with *H. pylori* is regarded as the most prominent risk factor for GC and is estimated to be responsible for at least 75% of human gastric adenocarcinomas.[39] However, while *H. pylori* colonizes the gastric epithelium of at least half of the world's population, only 1–3% of those infected will develop GC.[40,41] Factors attributing to this include duration of infection, bacterial pathogenicity,[42] polymorphisms in the host genome,[43,44] and diet, which collectively influence the extent and magnitude of the immune response. In particular, polymorphisms in inflammatory genes have attracted a considerable amount of attention, because infected patients carrying the *Il1β-511T* or *Il1β-31C* alleles not only exhibit augmented levels of IL-1β[45,46] but also have a higher risk of developing GC.[47,48] However, other epidemiological studies have revealed less clear links between *Il1β* polymorphisms and GC risk[49,50] and suggested a much larger number of susceptibility loci as well as environmental factors. Accordingly, models of long-term infections with *H. pylori* used in conjunction with the introduction of additional preconceived mutations and/or chemical agents have been useful for gaining insight into the molecular mechanisms underpinning *H. pylori*-mediated gastric carcinogenesis, at least in experimental mice (Table 2).

Helicobacter felis. Due to the resistance to colonization by *H. pylori* in mice,[51,52] *Helicobacter* infection models frequently exploit *H. felis*, a bacterial strain closely related to *H. pylori*, but derived from the gastric mucosa of cats.[53] Acute colonization of the mouse stomach with *H. felis* induces severe gastritis, and long-term infection often results in the development of atrophic lesions that form invasive adenocarcinomas.[10] Extensive dysplastic lesions are evident in the gastric corpus at the squamocolumnar junction after 12 months of infection,[54,55] while polyploid antral tumors are typically observed after 2 years and are pathologically similar to those observed in human patients.[53,55–57] Importantly, many of the early effects are reversible, because antibiotic treatment has been shown to reduce inflammation, restore normal gut architecture, and prevent the development of adenocarcinomas.[10,58] In line with these findings,

Table 1   GC susceptibility to MNU mutagenesis in different mouse strains

Strain	Incidence (affected/ total) (%)	Adenocarcinoma (affected/incidence)			Depth of invasion (affected/incidence)				Ref.
		WD	PD	SC	M	S	MP	SS	
BALB/c	20/27 (74)	18	1	1	2	12	3	—	Yamachika *et al.*,[26] Yamamoto *et al.*,[27] and Tatematsu *et al.*[165]
C3H/HeN	7/26 (26)	3	4	—	5	2	—	—	Yamamoto *et al.*[27] and Tatematsu *et al.*[123]
C57/Bl6	8/26 (30)	8	—	—	2	6	—	—	Yamamoto *et al.*[27] and Nakamura *et al.*[166]
CBA/JN	7/23 (30)	6	1	—	5	1	—	—	Yamamoto *et al.*[27]
CD-1 (ICR)	6/27 (22)	4	2	—	2	3	—	1	Yamamoto *et al.*[27]
DBA/2N	6/29 (20)	5	1	—	2	4	—	—	Yamamoto *et al.*[27]

GC, gastric cancer; M, mucosa; MNU, N-methyl-N-nitrosourea; MP, muscularis propria; PD, poorly differentiated; Ref., references; SC, signet cell type; S, submucosa; SS, subserosa; WD, well differentiated.

Table 2 Tumor characteristics in *Helicobacter*-infected mice

Model	AD onset (months)	AD incidence (%)	Location	Phenotype				Ref.
				AT	MT	DP	AD	
H. felis	18	80	Corpus	+	+	+	+	Fox *et al.*[54]
H. felis + MNU	9	100	Antrum	+	+	+	+	Tomita *et al.*[37]
H. felis + INS-GAS	8	85–100	Corpus	+	+	+	+	Fox *et al.*[108]
H. felis + IL1β	12	<70	Corpus + antrum	+	+	+	+	Tu *et al.*[119]
H. pylori + INS-GAS	8	100	Corpus	+	+	+	+	Fox *et al.*[75] and Fox *et al.*[108]
H. pylori + MNU	20	<80	Antrum	+	+	+	+	Nakamura *et al.*[166] and Han *et al.*[167]
H. pylori + MNU + high salt	10	100	Antrum	+	+	+	+	Toyoda *et al.*[76]

+, present; AD, adenocarcinoma; AT, atrophy; DP, dysplasia; MNU, N-methyl-N-nitrosourea; MT, metaplasia; Ref., references.

H. pylori eradication in patients with gastritis is the most effective way to decrease their risk of developing GC.[59]

H. pylori SS1 Sydney strain. A number of mouse-adapted *H. pylori* strains have now been developed, including the well-characterized Sydney strain (SS1).[60] After about 8 months of infection with this strain, mice develop severe gastritis and atrophy of the gastric epithelium, which may progress to high-grade dysplasia, although adenocarcinomas do not usually develop.[60,61] For this reason, *H. pylori* SS1 is typically used in conjunction with chemical agents or in genetically engineered mice to enable and promote gastric carcinogenesis. The inability of *H. pylori* SS1 to induce adenocarcinomas on its own is thought to be attributed to the loss of its *cag* pathogenicity island (CagA), which encodes a type IV secretion system that enables the bacterium to inject CagA, peptidoglycan, and other proteins into the host cell.[62] These latter proteins trigger the activation of signaling pathways comprising NF-κB, MAPK and STAT3, thereby promoting the production of inflammatory cytokines and chemokines.[63,64] Consistent with this, infection with CagA-positive *H. pylori* SS1 (PMSS1) induces rapid progression along the intestinal-type GC progression cascade.[65]

A reduction in *TFF1* gene expression is observed in 50% of human distal GCs and is associated with promoter hyper-methylation and the corresponding silencing of the *TFF1* gene.[66,67] Other factors that regulate TFF1 expression include gastrin, which stabilizes TFF1 and suppresses MNU-induced antral gastric tumor development.[27,37] Interestingly, *TFF1* is also epigenetically repressed in *H. pylori*-infected cells,[68] and *H. pylori* lipopolysaccharide associate with the TFF1 protein dimer *in vitro*.[37,69,70] Recently, loss of TFF1 was shown to promote *H. pylori*-induced β-catenin activation and the development of invasive adenocarcinomas in *Tff1*$^{-/-}$ mice, suggesting that the loss of TFF1 could be a critical step in promoting *H. pylori*-mediated oncogenic activation of β-catenin and gastric tumorigenesis.[71]

Advantages and limitations. *Helicobacter* infection models provide a robust and reproducible means to study immune responses during infection and chronic gastritis. For example, the increased susceptibility of C57BL/6 relative to BALB/c mice to *H. felis*-induced and *H. pylori* SS1-induced atrophies[60,72] has been attributed to a bias towards a T-helper-1 (Th1)-like immune response in C57BL/6 mice that is characterized by an increase in

IFN-γ and other pro-inflammatory cytokines.[72] Meanwhile, BALB/c mice display a bias towards Th2-like immune response characterized by increased IL-4, IL-10, and other cytokines. The critical role of cytokines in promoting *Helicobacter*-dependent gastritis severity and duration has also been demonstrated following infection of immune-deficient mice or of strains that overexpress IL-10[73] or IL-4.[74]

Mouse models of chronic *Helicobacter* infection have also highlighted the contribution to gastric carcinogenesis made by gender, diet, and the commensal microbiota. For instance, *H. pylori* infection of INS-GAS mice, a strain transgenically expressing gastrin from a rat insulin promoter fragment (see succeeding discussion), confers a greater gastric tumor incidence in males than in females, consistent with human epidemiological studies indicating a higher prevalence of GC in men.[75] Likewise, the carcinogenic link between infection and dietary salt and nitrates/nitrites intake has been demonstrated in C57/BL6 mice, which develop more pronounced gastric atrophy and a greater risk of adenocarcinomas following infection with *H. pylori* and a high-salt diet.[76] Finally, because gastric atrophy results from infection associated with the outgrowth of commensal bacteria that is enabled by the loss of acid-producing cells, the composition of the gut microbiota is considered another risk factor for GC. In line with this, infection studies using mice housed under germ-free conditions revealed that the lack of the commensal gut flora in *H. pylori*-infected INS-GAS mice reduced gastritis and delayed intraepithelial neoplasia.[77] Given that complete protection from intraepithelial neoplasia was not observed in this model, this indicates that the gastric microbiota has a tumor-promoting function rather than tumor-initiating function. In contrast, limitations of *Helicobacter* mouse models include the scarcity of *Helicobacter* strains and the extensive latency period of *H. pylori*-induced gastric atrophy and GC. Furthermore, there is a low incidence rate of advanced GC, and while *H. pylori* infection is an established causative factor of duodenal ulcers in humans, mouse models of *H. pylori* infection-induced duodenal ulcers have not been reported.[78]

Translational opportunities using Helicobacter infection models. The eradication of *H. pylori* in patients with established chronic infections is challenging. Current treatment strategies are focused on long-term maintenance therapy to prevent infection recurrence and typically include combining acid inhibition with a proton pump inhibitor and at least two

antibiotics. However, increasing antibiotic resistance and associated re-infection with *H. pylori* remains a significant hurdle in the clinic. *Helicobacter* infection models have been a useful tool for identifying new and improving existing treatment protocols for *H. pylori*-associated GC. Administration of the gastric acid inhibitors Omeprazole and Ranitidine following *H. pylori* infection was shown to improve the healing of macroscopic inflammatory lesions, indicating that partial acid blockade is effective at reducing disease pathology in mice.[79] The effect of long-term administration of the anti-inflammatory drugs Nimesulide (Cox-2 inhibitor) to *H. pylori*-infected mice that were also challenged with MNU significantly lowered the incidence of gastric tumors, indicating that *H. pylori*–associated inflammation was responsible for promoting gastric carcinogenesis in this model. Interestingly, Nimesulide treatment also markedly reduced atrophic gastritis.[80]

Therapeutic targeting of ulcers with Rebamipide has had positive effects on gastritis after long-term treatment. Notably, Rebamipide decreased expression of ICAM1, HCAM and MMPs, and other inflammation related proteins, and decreased NF-κB-dependent DNA-binding activity accordingly.[80] Together, these results support the concept that long-term administration of these anti-inflammatory molecules may reduce the risk of GC development in *H. pylori*-infected individuals.

Although antibiotic treatment clearly shows effectiveness in controlling *Helicobacter* infection in mice, the response in a specific preclinical model is likely to be affected by compounding mutations and genetic polymorphisms carried by the host. *H. pylori* infection of p27-deficient mice, for instance, revealed that a combination treatment regime of Omeprazole, Metronidazole, and Clarithromycin controlled infection equally well irrespective of whether the treatment occurred 15 or 45 weeks post-infection, with both groups scoring similarly for inflammation, epithelial defects, metaplasia, and atrophy.[81] By contrast, *H. pylori* eradication in INS-GAS mice was more effective when therapeutic intervention was administered at an early point of infection.[58]

The emergence of antibiotic resistance against *H. pylori* has spurred considerable efforts to develop small molecule inhibitors with high specificity against bacterial virulence factors. For example, treatment of *H. pylori*-infected mice with a small molecule

inhibitor against CagA impaired gastric colonization and alleviated disease.[82] Other targets include pathways required by the bacterium to survive, including the metabolic conversion of urea to ammonia and bicarbonate by-products. Accordingly, treatment of infected mice with the urease inhibitor Fluorofamide significantly decreased *H. pylori* colonization.[83] In another study, the small molecule inhibitor HPi1 reduced *H. pylori* colony counts to below detectable limits.[84] Collectively, these results validate mouse models for *Helicobacter* infection as important platforms for the development and testing of potential therapeutic candidates against this disease.

Genetic and chemically induced models of premalignant states

Intestinal-type GC is preceded by a sequence of histologically discrete stages that include chronic gastritis, atrophy, metaplasia, and dysplasia. In addition to mouse models of GC, several models of atrophy and metaplasia have also been developed to determine if early intervention at these stages may assist in GC prevention. Here, we focus on some models of atrophy and metaplasia including the commonly used H/K-ATPase transgenic mutant mice (Fig. 3) and also briefly outline the histopathological characteristics of other established models in Table 3.

H/K-ATPase transgenic and knock-out mutants.
The secretion of hydrochloric acid in the stomach is dependent on H/K-ATPase, a heterodimeric enzyme localizing to the tubulovesicular and canalicular membranes of parietal cells.[85] H/K-ATPases are required for parietal cell viability and normal development of the gastric mucosa, because H/K-ATPase inhibition with Omeprazole results in parietal cell degeneration and expansion of pre-parietal cell compartments.[86] The latter results were also replicated following parietal cell ablation through transgenic expression of the diphtheria toxin under the control of the H/K-ATPase gene promoter.[8,87] Given that the loss of mature parietal cells in these models also resulted in a concomitant loss of chief cells and an increase in progenitor cells, H/K-ATPases may also have a function to maintain gastric gland homeostasis by

Figure 3 Chemical and genetic models of gastric cancer (GC). GC is preceded by a series of discrete stages that include chronic gastritis, atrophy, metaplasia, and dysplasia. In addition to chemically and genetically induced models of GC (blue boxes), mice that develop atrophy (pink boxes) and metaplasia (green boxes) have also been developed and used to determine if early intervention at these stages may assist in treatment and prevention of GC. These mouse models exhibit manipulation of genes that result in overexpression or deficiency in growth factors (including hormones and cytokines), as well as mutations in tumor suppressors and oncogenes.

Table 3 Mouse models of gastric atrophy and metaplasia

Model	Onset	Phenotype	Ref.
CAG-BTC	4 months	Atrophy	Dahlhoff et al.[99]
Car9$^{-/-}$	1 month	Atrophy	Gut et al.[91]
Cck2r$^{-/-}$	4 months	Atrophy	Nagata et al.[168]
H/K-ATPase:Cdx1 and H/K-ATPase:Cdx2	4 months	Metaplasia	Mutoh et al.[95] and Silberg et al.[92]
DMP-777	1–2 weeks	Atrophy + SPEM	Goldenring et al.[100]
[†]H/K-ATPase-$\alpha$$^{-/-}$	3 months	Atrophy + IM	Spicer et al.[88] and Judd et al.[89]
[†]H/K-ATPase-$\beta$$^{-/-}$	17 days	Atrophy + IM	Scarff et al.[90] and Franic et al.[170]
[†]H/K-ATPase-β/DT	1–11 months	Atrophy	Li et al.[8]
H/K:Ifn-γ	5–15 months	SPEM	Syu et al.[171]
Shh$^{-/-}$	3–8 months	Atrophy	Xiao et al.[172]
L-635	1 week	Atrophy + SPEM	Nam et al.[173]
Nhe2$^{-/-}$	17 days	Atrophy	Schultheis et al.[174]
MT:Tgf-α	3 months	Atrophy	Takagi et al.[97]
Waved-2 + DMP-777	1 week	SPEM	Ogawa et al.[102]

[†]Commonly used model
DT, diphtheria toxin; Ref., references; SPEM, spasmolytic polypeptide expressing metaplasia.

regulating the differentiation and maturation of other epithelial cell types in the stomach.

Surprisingly, the two subunits of H/K-ATPase have both overlapping as well as non-overlapping functions, which have been revealed by genetic ablation studies. While α-subunit-deficient and β-subunit-deficient strains both develop achlorhydria and hypergastrinemia, loss of the β-subunit selectively also results in gastric mucosal hypertrophy and a reduced number of chief cells.[88–90] Meanwhile, loss of the α-subunit confers an age and gender-dependent (female-biased) gastric hyperplasia with incomplete intestinal metaplasia from 3 months of age, which is associated with a significant increase in *RegIIIγ* and *RegIIIδ* mRNAs.[89]

Car9$^{-/-}$ mice. Carbonic anhydrase is present in the basolateral membranes of gastrointestinal epithelial cells where it regulates acid–base balance and intercellular communication.[91] It is aberrantly expressed in many carcinomas including GC. Mice with null mutations of the corresponding *Car9* gene develop gastric hyperplasia of the glandular epithelium by 1 month of age, which is characterized by the overproduction of mucous-secreting pit cells and the depletion of pepsinogen-positive chief cells.[91] While the hyperplastic phenotype of Car9$^{-/-}$ mice shares many features of hyperplasia observed in mice lacking the β-subunit of H/K-ATPase, this model also differs in several aspects. For instance, unlike H/K-ATPase:$\beta$$^{-/-}$ mice, Car9$^{-/-}$ animals do not develop hypergastrinemia and hypochlorhydria. Because Car9$^{-/-}$ mice show normal gastric acidity, this suggests that the *Car9* gene plays a more extensive role in regulating differentiation and proliferation of gastric mucosal cells, rather than being limited to acid production.

Cdx1 and Cdx2 transgenic mice. Cdx1 and Cdx2 are intestine-specific transcription factors that belong to the caudal-related homeobox gene family. In the normal intestine, Cdx2 is expressed in differentiated epithelial cells of the villi (i.e. in absorptive enterocytes, goblet, and enteroendocrine cells), while Cdx1 expression is predominately localized to proliferating cells

towards the base of intestinal crypts.[92,93] Although the normal gastric mucosa does not express Cdx1 and Cdx2, strong nuclear immunoreactivity is thought to molecularly underpin intestinal metaplastic transformation observed in the gastric mucosa of patients.[94] Indeed, enforced expression of Cdx1 or Cdx2 in the glandular epithelium of the stomach using the H/K-ATPase β-subunit gene promoter leads to the development of intestinal metaplasia in transgenic mice.[92,93] Interestingly, intestinal metaplasia in H/K-ATPase:Cdx2 transgenic mice is characterized by the appearance of absorptive enterocytes, goblet, and enteroendocrine cells, while H/K-ATPase:Cdx1 transgenic mice exhibit intestinal metaplasia comprising all four intestinal epithelial cell types.[95] Moreover, pseudopyloric gland metaplasia is only observed in H/K-ATPase:Cdx2, but not in H/K-ATPase:Cdx1 animals, and the proliferating cell nuclear antigen shows scattered expression throughout the metaplastic areas H/K-ATPase:Cdx1 mice rather than the staining at the base of the glands observed in H/K-ATPase:Cdx2 animals.[95] Collectively, these results indicate that Cdx1 and Cdx2 are both able to induce intestinal metaplasia albeit with subtle differences in cellular differentiation and proliferation.

EGFR dependent hyperplasia: TGFα and BTC transgenic mice. Ménétrier's disease is a potentially premalignant human gastric disorder characterized by hypertrophy of the gastric mucosa, atrophy of the glandular compartment, foveolar hyperplasia, and cystic dilation of gastric glands.[96] Ménétrier's disease patients show increased expression of the epidermal growth factor receptor (EGFR) ligands transforming growth factor-alpha (TGFα) and betacellulin (BTC) and therefore can be treated with the anti-EGFR monoclonal antibody Cetuximab.[96] Indeed, 3-months-old mice that were engineered to overexpress TGFα in the fundic mucosa develop foveolar hyperplasia, characterized by achlorhydria and excessive mucous production.[97,98] Likewise, BTC overexpression results in severe age-dependent hyperplasia of the foveolar epithelium with the formation of large cysts and extensive depletion of the gastric mucosa.[99]

DMP-777 treatment. DMP-777 is a potent leukocyte elastase inhibitor, which also acts as a parietal cell-specific proton translocator to facilitate proton exchange across lipid bilayers. However, high doses of DMP-777 have also been shown to damage membranes of acid-secretory vesicles in parietal cells and promote hypochlorhydria and increased serum gastrin levels.[100] After 3 days of DMP-777 exposure, mice develop acute oxyntic atrophy, which precedes prominent foveolar hyperplasia. By 7–10 days, SPEM develops in the fundus, suggesting that the induction of gastric metaplasia is a direct consequence of parietal cell loss. Interestingly, withdrawal of DMP-777 leads to complete restitution of the normal mucosa within 3 months, consistent with the capacity of parietal cells to maintain normal gastric mucosal functions.[100] Because DMP-777 inhibits neutrophil elastase, and therefore prevents the accumulation of inflammatory cell infiltrates, long-time administration does not result in dysplasia even in the presence of severe oxyntic atrophy and SPEM.[100] It is likely that DMP-777 during inflammation promotes tumor progression following an oncogenic mutation in susceptible epithelial cells.

The use of DMP-777 in genetically modified mouse models has been helpful to better understand the contributions of gastrin,[101] EGFR ligands, and other signaling molecules to SPEM.[102,103] While continuous DMP-777 treatment of wild-type mice rapidly induced foveolar hyperplasia, hypergastrinemia and SPEM as described previously, a single dose of DMP-777 in gastrin-deficient mice was sufficient to induce oxyntic atrophy and SPEM in the absence of foveolar hyperplasia.[101] Thus, the lack of gastrin is likely to promote SPEM in response to oxyntic atrophy by trans-differentiation of chief cells.[101] Likewise, DMP-777 treatment of Waved-2 mice carrying a hypomorphic mutation in the EGFR tyrosine kinase (Egfr[wa2]), or mice deficient for the EGFR ligand amphiregulin, accelerated the development of SPEM.[102,103]

Interestingly, loss of TGFα did not influence SPEM induction, indicating that specific EGFR ligands play key roles in regulating the induction of metaplasia in DMP-777 treated mice.[103]

Genetic models of GC

Genetically engineered mice have helped to elucidate the contribution of mutations in the neoplastic gastric epithelium and the surrounding host tissue (Fig. 3). These models have exploited standard recombinant DNA technology to modify the germline of mice to achieve overexpression or deficiency in growth factors (including hormones and cytokines and their receptors), as well as mutations in tumor suppressors and oncogenes. Here, we discuss some of the most commonly used mouse models of GC including the INS-GAS, H/K-ATPase:*IL-1β*, and Gp130[F/F] mutant mouse strains, as well as briefly summarize the histopathology of a selection of others (Table 4).

Gastrin mutants. Gastrin is a hormone produced by G cells in the antral mucosa, which regulates acid secretion in response to food intake, maintains gastric architecture, and promotes homeostatic renewal of the gastric epithelium.[104] Accordingly, gastrin regulates cell division, invasion, angiogenesis, and apoptosis.[105] Therefore, mouse models were developed to either excessively express gastrin (in INS-GAS transgenic mice) or to completely ablate gastrin expression (in Gas[−/−] knockout mice).

INS-GAS mice. INS-GAS mice express human gastrin under the control of the insulin promoter yielding a twofold increase of amidated gastrin in the serum of these mice.[106] In the absence of *Helicobacter* infection, INS-GAS mice show an increase in gastric

Table 4 Genetic mouse models for GC

Model	Onset	Incidence, %	Location	Type	Inv.	Met.	Ref.
ACT-GAS	20 months	100	Corpus	WD	−	−	Kanda *et al.*[175]
CA-AhR	12 months	100	Corpus	WD	+	+	Andersson *et al.*[176]
CEA-SV40	7 weeks	100	Antrum	WD	+	−	Thompson *et al.*[177]
Atp4b-Cre; Cdh1[loxP/loxP]; p53 [loxP/loxP]	12 months	100	Corpus	PD	+	+	Shimada *et al.*[178]
Cdh1[+/−] + MNU	10 months	46	Antrum	PD	−	−	Humar *et al.*[34]
H/K-ATPase:Cdx2	3 months	100	Corpus	WD	+	−	Mutoh *et al.*[179]
Gas[−/−]	12 months	60	Antrum	WD	−	−	Zavros *et al.*[9]
GB-Cre;Smad4[Floxed]	18 months	100	Antrum	WD	−	−	Hahn *et al.*[180]
Gp130[F/F]	3 months	100	Corpus + antrum	WD	−	−	Ernst *et al.*[126]
INS-GAS	20 months	75	Corpus	WD	+	−	Fox *et al.*[108]
K19:Kras-(V12D)	16 months	38	Corpus	WD	+	−	Okumura *et al.*[143]
H/K-ATPase:IL1β	18 months	30	Antrum	WD	−	−	Tu *et al.*[119]
Runx3[−/−] + MNU	1 year	60	Corpus + antrum	WD	−	−	Ito *et al.*[33]
Lgr5[CreERT2];APC[Floxed]	3 weeks	100	Antrum	WD	−	−	Barker *et al.*[181]
MMTV-Ad12	4 months	56	SCJ	WD	+	+	Koike *et al.*[182]
Mth1[−/−]	18 months	13	Antrum	WD	−	−	Tsuzuki *et al.*[183]
Smad3[−/−]	10 months	100	SCJ	WD	+	−	Nam *et al.*[184]
Smad4[+/−]	18 months	100	Corpus + antrum	WD	+	−	Takaku *et al.*[185]
Tff1[−/−]	5 months	30	antrum	WD	+	−	Lefebvre *et al.*[151]
K19-Wnt1:C2mE	5 months	100	SCJ	WD	+	−	Oshima *et al.*[186]
Villin-Cre;KLF4[Floxed]	20 months	29	Antrum	WD	−	−	Li *et al.*[35]

+, present; −, absent; GC, gastric cancer; Inv., invasion; Met., metastasis; PD, poorly differentiated; Ref., references; SCJ, subcolumnar junction; WD, well differentiated.

acid secretion and parietal cell mass at 1–3 months of age and eventually develop atrophy as a result of hypergastrinemia. However, *H. pylori*-infected INS-GAS mice develop intramucosal carcinomas with submucosal and intravascular invasion by less than 1 year, which subsequently progress to tumors in the gastric corpus of 20-month-old mice.[107,108] Interestingly, gender is a major modifier of *H. pylori*-associated GC in INS-GAS mice, with males exhibiting a higher incidence than females.[75] This gender bias is attributed to estrogen, because ovariectomized female INS-GAS mice are equally susceptible to *H. pylori*-induced gastric neoplasia as their male littermates.[109] Furthermore, GC development in INS-GAS mice is also influenced by genetic background, because all of the aforementioned observations are only made in mice on the FVB genetic background, while on the C57BL/6 background even *Helicobacter*-infected INS-GAS mice only develop hyperplasia and dysplasia in the corpus region.[110]

Due to the extensive latency period of *H. pylori* infection-dependent induction of gastric atrophy and GC in wild-type mice, such studies are frequently performed with INS-GAS mice to accelerate GC, and to study the effect of compounding gene mutations in the host,[111] of the microbiota,[108] and gender.[109] Conversely, this model has also served to identify potential prophylactic strategies for GC. Combination treatment with the nonsteroidal anti-inflammatory drug Sulindac and the triple antibiotic (Omeprazole, Metronidazole, and Clarithromycin) *H. pylori* eradication therapy was beneficial for reducing the production of pro-inflammatory cytokines in the stomach and preventing the progression from severe dysplasia to GC.[112] Similarly, *H. felis*-infected INS-GAS mice treated with the gastrin receptor antagonist YF476, or with the histamine receptor antagonist Loxitidine, resulted in partial suppression of gastric acid secretion and neoplastic progression, which was further reduced when combining the two drugs.[113] These latter findings support an important role for the gastrin–histamine axis in *Helicobacter*-induced gastric carcinogenesis and raise the possibility for this drug combination (YF476 and Loxitidine) to serve as an alternative clinical approach for long-lasting acid suppression. Given the male bias for *H. pylori*-associated GC incidence, Ins-Gas mice have also been used to establish that estrogen supplementation protects male mice against gastritis and premalignant gastric lesions.[109]

Gas$^{-/-}$ *mice.* Hypogastrinemia is an established risk factor for the development of gastric ulcers, and the associated achlorhydria is likely to predispose GC. On a C57BL/6 background, gastrin knockout (Gas$^{-/-}$) mice exhibit mild changes in gastric architecture, characterized by a decrease in parietal and enterochromaffin-like cells.[105] However, when crossed onto the 129/Sv background, achlorhydria results in bacterial overgrowth and chronic inflammation.[114] On an FVB background, 1-year-old Gas$^{-/-}$ mice develop spontaneous antral tumors, which can be accelerated following exposure to MNU.[9,37] Interestingly, antibiotic treatment of young GAS$^{-/-}$ mice on an 129/Sv background reversed fundic and antral hyperplasia,[114] while exogenous gastrin administration temporarily prevented both intestinal metaplasia and the upregulation of an interferon-dependent transcriptional response.[115] However, progressive and irreversible intestinal metaplastic changes eventually develop in aging C57BL/6 Gas$^{-/-}$ mice and result in tumor development.[115] Given the differences in susceptibility

and disease onset between genetic backgrounds, these results re-affirm the importance of choosing the appropriate strain when considering the use of these models for studying GC pathogenesis.

Although the molecular mechanisms by which gastrin deficiency promotes GC remain unclear, several mechanisms have been proposed. Because achlorhydria enables enterococal overgrowth in Gas$^{-/-}$ mice, these bacteria can produce carcinogenic by-products such as N-nitrosamines through the metabolism of nitrates.[114,115] In support of this, increased production of N-nitrosamines is also observed in atrophic gastritis patients with achlorhydria, which is consistent with their increased risk for GC.[116] Secondly, because bacterial infection initiates an inflammatory response associated with increased expression of IFN-γ and other cytokines, bacterial overgrowth is likely to alter gastric gene expression and promote tumor formation.[115] One such example is the inverse correlation between Cdx2 activation and luminal acidity in the duodenum.[117] The increased activation of transcription factors such as Cdx2 and tumor development correlates with achlorhydria severity in the stomach.[115] Thus, gastrin deficiency in Gas$^{-/-}$ mice is most likely to facilitate malignant transformation by exacerbating achlorhydria in the stomach. Comparison between the INS-GAS and Gas$^{-/-}$ models has also revealed distinct roles for gastrin in distinct anatomical sections of the stomach, because tumor development is restricted to the corpus and antrum of these mice, respectively, and MNU-treated INS-GAS mice do not readily develop antral tumors.[37] Collectively, these findings highlight the importance of considering the corpus and antrum as distinct anatomical sites when characterizing tumor pathology in mouse models.

H/K-ATPase:IL-1β transgenic mice. IL-1β is a pleiotropic inflammatory cytokine regulating cellular proliferation, differentiation, and apoptosis. IL-1β is excessively expressed in response to *H. pylori* infection,[118] and polymorphisms in *IL-1β* gene have been linked to increased risk of *H. pylori*-associated gastric carcinogenesis.[47,48] Experimental insights into the role of IL-1β during epithelial homeostasis have largely been gained from mice that express constitutive IL-1β activation. These H/K-ATPase:IL-1β transgenic mice spontaneously develop inflammation, atrophy, metaplasia, and gastric adenocarcinomas in 30% of mice by 18 months of age.[119] When infected with *H. felis*, tumor development in these mice is accelerated and occurs within 1 year of age, thereby confirming a link between elevated IL-1β and an increased risk for inflammation-associated GC.[119]

Several mechanisms underpinning IL-1β-associated GC have been identified using the IL-1β transgenic mouse model. These include excessive activation of the NF-κB pathway, resulting in elevated levels of pro-inflammatory cytokines such as IL-1β, IL-6, IFN-γ, and TNFα,[119] as well as an increased recruitment of myeloid-derived suppressor cells to the gastric epithelium where they suppress the host's anti-tumor immune response.[120] IL-1β has also been shown to promote gastric atrophy by suppressing Sonic hedgehog gene expression in parietal cells, resulting in decreased acid secretion and release of intracellular calcium.[121]

The IL-1β transgenic mouse has substantially contributed to our understanding of the role of stromal cells including

cancer-associated fibroblasts (CAFs) in gastric tumorigenesis. Although it was widely accepted that the interaction between tumor cells and CAFs promotes tumorigenesis, the precise role of these cells remain unclear. However, in this model, CAFs accumulated during chronic inflammation, particularly during dysplasia, and these CAFs were also αSMA-positive, a marker of myofibroblasts, and derived from the bone marrow.[122] During chronic inflammation and tumorigenesis, these αSMA-positive CAFs expanded and migrated in a TGF-β-dependent and SDF-1α-dependent manner to incipient tumor cells where they contributed to and sustained tumor growth by expressing IL-6, Wnt5α, and BMP4.[122] In another study, the role of T-cells in GC was analyzed to show that IFN-γ overexpression inhibited gastric carcinogenesis because of suppression of Th1 and Th17 immune responses by IFN-γ through Fas induction and apoptosis of CD4 T-cells.[123]

Gp130^{F/F} mice. Increased activation of the latent transcription factor STAT3 is frequently observed in many solid human malignancies including GC.[124] However, while excessive STAT3 signaling promotes upregulation of genes involved in angiogenesis, cell-cycle progression, and cell survival, the complex role of STAT3 during tumor progression is still incompletely understood.[124,125] One approach to explore the role of excessive STAT3 activity in response to the IL-6 family of cytokines exploited a phenylalanine knock-in substitution at tyrosine 757 in the cytoplasmic domain of the IL-6 receptor β-chain Gp130, which prevents binding of the STAT3 negative regulator suppressor of cytokine signaling (SOCS)3.[126] Accordingly, the homozygous presence of this mutation in the corresponding Gp130^{F/F} mutant mice facilitates excessive activation of STAT3 and to a lesser extent of STAT1.[127] Gp130^{F/F} mice develop splenomegaly and rapid tumor development in the epithelium of the glandular stomach independent of *H. pylori* infection and highlight a key role for STAT3 signaling in promoting gastric tumorigenesis.[126] Alongside STAT3 activation, excessive activation of the mTOR complex 1 (mTORC1) has also been reported in Gp130^{F/F} mice, while administration of an mTORC-1 inhibitor suppressed tumor development and progression.[128] Interestingly, gp130-dependent activation of mTORC1 was found to occur via PI3K/AKT and require Janus kinases (JAK), but neither STAT3 nor phosphorylation of tyrosines on gp130.[128] Because tumors in Gp130^{F/F} mutants resemble well-differentiated human gastric adenocarcinomas, these results indicate an essential role for the PI3K/mTORC1 pathway in inflammation-associated tumorigenesis that could be therapeutically exploited.

The development of tumors in Gp130^{F/F} mutants follows the classical intestinal-type developmental sequence, although these lesions rarely become invasive and never metastasize to distant organs. Corpus hyperplasia in Gp130^{F/F} mice occurs from 14 weeks of age, while antral tumors can be observed from 6 weeks onwards.[126] In addition to increased expression of anti-apoptotic and pro-angiogenic genes,[129,130] excessive STAT3 activation also correlates with increased *Tlr2* expression in these tumors, while genetic ablation of *Tlr2* alleviates gastric tumor formation independent of inflammation.[131] Interestingly, *TLR2* expression is elevated in *H. pylori*-positive patients, and *TLR2* polymorphisms are associated with an increased risk for GC.[132–134]

TLR2 signaling is thought to involve the adapter proteins MyD88 and Mal, which promote activation of NF-κB, p38, and MAPK pathways. Interestingly, genetic ablation of *Myd88* in Gp130^{F/F} animals suppressed tumorigenesis to a level comparable with Gp130^{F/F}; Tlr2^{−/−} mice, while the tumor burden of Gp130^{F/F};Mal^{−/−} compound mutants remained similar to that of their Gp130^{F/F} littermates.[135] Given the interest in developing small molecular inhibitors against TLR2 for human GC,[136,137] the use of the Gp130^{F/F} mouse as a model for the testing of anti-TLR2 molecules has already shown favorable results.[131]

In addition to providing insight into the mechanisms of STAT3-mediated tumorigenesis, the Gp130^{F/F} mouse model has also served as an important tool for the identification and validation of novel therapeutics against STAT3 signaling. One example is the targeting of gp130-associated JAK kinases, which phosphorylate cytoplasmic STAT3 to promote its dimerization, nuclear translocation, and transcriptional activity.[138] Accordingly, systemic administration of the small molecule JAK1/2 inhibitor AZD1480 attenuated tumor progression in Gp130^{F/F} mice, which was associated with reduced STAT3 activation, diminished tumor cell proliferation, and increased apoptosis.[139] Likewise, treatment of Gp130^{F/F} mice with the JAK inhibitor WP10336 for 2 weeks reduced gastric tumor volume by 50% and correlated with reduced JAK2 and STAT3.[140] Although these results provide a strong rationale for pharmacological targeting of JAK kinases, systemic inhibition of JAK2 in mice and humans can also cause thrombocytopenia and other undesired on-target side-effects.[141] Given the prominent role of IL-11 in the development and progression of inflammation-associated GC, this cytokine has raised considerable interest as a potential therapeutic target associated with fewer adverse effects.[127] In particular, we have shown that treatment with an IL-11 antagonist, IL-11 Mutein, reduced STAT3 activation and significantly inhibited tumor development and gastric epithelial hyperplasia in Gp130^{F/F} mice.[127] Importantly, IL-11 Mutein treatment for 4 weeks did not result in side-effects, in particular, when assessing hematopoietic parameters,[127] supporting IL-11 signaling as a potential therapeutic target for GC.

K-Ras transgenic mice. The small GTP-binding protein K-Ras belongs to the superfamily of RAS-like GTPases and regulates cell-cycle progression, apoptosis, and senescence and activates somatic mutations in *K-RAS* lock the protein in a GTP-bound, permanently active form.[142] While less prevalent than other mutations, activating mutations in *K-RAS* have also been observed in GC, and these have been shown to promote proliferation and tumor cell invasiveness.[142]

The role of K-Ras in the pathogenesis of GC has been explored with several oncogenic K-Ras mutant mouse strains. One model exploits the K19-promoter to constitutively express the oncogenic K-Ras(V12D) gene. These K-Ras(V12D) transgenic mice exhibit metaplasia, dysplasia, and adenocarcinoma formation in 38% of the mice by 16 months of age, correlating with enhanced recruitment of inflammatory cells and fibroblasts, as well as elevated levels of CXCL1 and other chemokines.[143] In contrast, when the K-Ras(G12D) mutation is targeted to the gastric epithelium, hyperplasia, metaplasia, and adenocarcinoma are observed.[144] Interestingly, ubiquitous K-Ras activation in K-Ras(G12D/+) mice results in accelerated

inflammation, hyperplasia, and metaplasia in the stomach, although neoplastic changes are not observed.[145] Together, these results suggest that oncogenic mutations in K-Ras are required in a specific cell type for the progression from tumor to cancer.

Tff1^{−/−} mice. *Tff1*^{−/−} *mice.* Trefoil factor 1 (TFF1) is a protein that appears to confer a tumor suppressor role and is predominantly expressed by surface mucosal cells of the stomach where it regulates the normal differentiation of gastric glands.[146] Through its interaction with various mucins, TFF1 promotes correct organization of the mucous layer and protection of the gastric mucosa from erosion.[147] In support of this, TFF1 expression increases in inflamed and damaged gastrointestinal tissues,[148,149] and iFABP: pS2 mice overexpressing the Tff1/pS2 transgene exhibit an increased resistance to ulceration.[150] By contrast, Tff1^{−/−} mice develop glandular hyperplasia characterized by crypt elongation and nuclei enlargement associated with loss of cell polarity from 3 weeks of age, and invasive adenocarcinomas are observed in 30% of mice at 5 months.[151] In support of the role of inflammation in gastric carcinogenesis, loss of *Tff1* promotes activation of the canonical NF-κB signaling pathway and results in increased immune cell infiltration into the submucosa and glandular epithelia.[152] Tumors from Tff1^{−/−} mice also express elevated levels of COX-2,[153] which has been suggested to indicate reduced survival of human GC patients.[154] However, whereas COX-2 is similarly expressed in hyperplastic gastric tissue and gastric adenomas of Tff1^{−/−} mice, COX-2 expression increases with disease severity in human precursor lesions.[155] In Tff1^{−/−} animals COX-2 expression appears to be restricted to stromal cells, whereas in human GC patients, COX-2 is mostly associated with epithelial cells.[155,156] Nevertheless, early treatment with the COX-2 inhibitor Celecoxib has been shown to reduce adenomatous growth in Tff1^{−/−} mice, while treatment of mice with fully developed adenomas led to a significant reduction in tumor multiplicity and size.[157] However, withdrawal of Celecoxib triggered the reappearance of adenomas,[157] suggesting that reciprocal increase in COX-2 activity following Tff1 deletion functions as a tumor promoting mechanism.

Future perspectives

Although various mouse models with distinct susceptibilities to GC development and pathologies are now readily available for the study of gastric tumorigenesis, the molecular mechanisms that underpin GC development remain incompletely understood. Genome-wide sequencing studies have been useful in identifying additional epigenetic and genetic changes that significantly impact GC development and progression. Recent sequencing studies on human gastric tumors have associated new mutations in genes such as *PSCA*[158] and *PLCE1*[159] with increased susceptibility to develop GC, while other studies have identified genes in GC subtypes associated with distinct clinical outcomes.[6] Targeting these genes in the context of mouse models is likely to provide insights into their causal mechanism by which they affect the development and progression of GC.

One major limitation is the scarcity of models in which mutations are only targeted to specific gastric cell lineages. The use of DNA recombinases, such as Cre, will enable induction of mutations in the various gastric epithelia and evaluate the potential of these cells to give rise to solid cancers. This, however, will require the identification of promoter sequences that restrict transgene expression to the specific gastric epithelial cells. For example, drivers such as K19:Cre and Foxa3:Cre are also expressed in the colon and intestine, while a Tff1:CreERT2 driver confers recombination to the glandular epithelium of the stomach.[160] A number of studies have identified potential stem-cell markers for gastrointestinal tissues. However, many of these markers such as Lgr5 and Lrig[161] are not exclusively expressed in the stomach. Other potential candidates include TFF2 and Mist1.[162,163] TFF2-expressing cells are observed in the base of antral glands as well as the isthmus, where they give rise to mucous neck, parietal, and zymogenic cells.[163] In contrast, *Mist1* expression is restricted to mature chief cells that have been shown to give rise to SPEM after exposure to DMP-777 treatment or *H. felis* infection,[162] while TFF1 has already been used as a promoter to disrupt TGF-β2 signaling in the gastric mucosa[164] and TFF2:CreERT and Mist1:Cre mice are available. Further investigation of basic gastric biology through lineage tracing studies needs to be performed to identify further epithelial cell, and potentially stem cell, markers with exclusive specificity in the stomach. These studies when combined with existing GC models would fast track the identification of potential therapies for clinical trials with life-sustaining effects.

Conclusion

Mouse models of GC have progressed over recent decades from chemically induced random mutagenesis, to bacterial-induced dysplasia and more recently to recombinant DNA technology-mediated genetic mouse models. These models have revolutionized our understanding of how genes, diet, bacteria, and host immunity affect GC formation. Furthermore, mouse models of precancerous change have shed light on the molecular mechanisms by which these changes affect early stages of carcinogenesis, aided clinical detection, and have pinpointed therapeutic strategies for intervention at the pre-neoplastic stages. Given the large number of models available, an in-depth understanding of their tumor histopathology and molecular signatures is important to ensure that new pre-clinical drug studies exploit the model that is most relevant to the hypothesis investigated. Clearly, factors such as genetic background, gender, diet, and the gut microbiota associated with housing conditions impact on the various models and thus need to be carefully controlled for when interpreting results. The incorporation of current research methods such as genome/exome-wide sequencing and lineage tracing has yielded fantastic results in the field of colorectal cancer and will provide the foundation for similar advancements on disease mechanisms and identification of therapeutic targets for clinical trials.

Acknowledgments

References

1 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin D. Estimates of worldwide burden of cancer in 2008. *Int. J. Cancer* 2010; **127**: 2893–917.

2 Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. *Lancet* 2009; **374**: 477–90.

3 Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J. Clin.* 2011; **61**: 69–90.

4 Yuasa Y. Control of gut differentiation and intestinal-type gastric carcinogenesis. *Nat. Rev. Cancer* 2003; **3**: 592–600.

5 TCGA. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014; **513**: 202–9.

6 Cristescu R, Lee J, Nebozhyn M *et al*. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. *Nat. Med.* 2015; **21**: 449–56.

7 Fox J, Wang T. Inflammation, atrophy and gastric cancer. *J. Clin. Invest.* 2007; **117**: 60–9.

8 Li Q, Karam S, Gordon J. Diphtheria toxin-mediated ablation of parietal cells in the stomach of transgenic mice. *J. Biol. Chem.* 1996; **271**: 3671–6.

9 Zavros Y, Eaton K, Kang W *et al*. Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma. *Oncogene* 2005; **24**: 2354–66.

10 Cai X, Carlson J, Stoicov C, Li H, Wang T, Houghton J. *Helicobacter felis* eradication restores normal architecture and inhibits gastric cancer progression in CD57BL.6 mice. *Gastroenterology* 2005; **128**: 1937–52.

11 Goldenring J, Nomura S. Differentiation of the gastric mucosa III. Animals models of oxyntic atrophy and metaplasia. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2006; **291**: G999–G1004.

12 Hattori T. Development of adenocarcinomas in the stomach. *Cancer* 1896; **57**: 1528–34.

13 Schmidt P, Lee J, Joshi V *et al*. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. *Lab. Invest.* 1999; **79**: 639–46.

14 Halldorsdottir A, Sigurdardottir M, Jonasson J *et al*. Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. *Dig. Dis. Sci.* 2003; **48**: 431–41.

15 Carl-McGrath S, Ebert M, Rocken C. Gastric adenocarcinoma: epidemiology, pathology and pathogenesis. *J. Cancer Ther.* 2007; **5**: 877–94.

16 Busuttil RA, Zapparoli GV, Haupt S *et al*. Role of p53 in the progression of gastric cancer. *Oncotarget.* 2014; **5**: 12016–26.

17 Park W, Oh R, Park J *et al*. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. *Cancer Res.* 1999; **59**: 4257–60.

18 Mattioli E, Vogiatzi P, Sun A *et al*. Immunohistochemical analysis of pRb2/p130, VEGF, EH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. *J. Cell. Physiol.* 2007; **210**: 183–91.

19 Li X, Yue Z, Zhang Y *et al*. Elevated serum level and gene polymorphisms of TGF-beta1 in gastric cancer. *J. Clin. Lab. Anal.* 2008; **22**: 164–71.

20 Stock M, Otto F. Gene deregulation in gastric cancer. *Gene* 2005; **360**: 1–19.

21 Barber M, Murrell A, Ito Y, Maia A, Hyland S, Oliveira C. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. *J. Pathol.* 2008; **216**: 295–306.

22 Potten C, Darzynkiewicz Z, Sasaki K, Buono RD, Pignatelli M. The role of the E-cadherin complex in gastrointestinal cell differentiation. *Cell Prolif.* 2003; **32**: 79–84.

23 Handschuh G, Candidus S, Luber B *et al*. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. *Oncogene* 1999; **18**: 4301–12.

24 Mayer B, Johnson JP, Leitl F *et al*. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. *Cancer Res.* 1993; **53**: 1690–5.

25 Zheng H, Takahashi H, Murai Y *et al*. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. *J. Clin. Pathol.* 2007; **60**: 273–7.

26 Yamachika T, Nakanishi H, Inada K *et al*. N-Methyl-N-nitrosourea concentration-dependent, rather than total intake-dependent, induction of adenocarcinomas in the glandular stomach of BALB/c mice. *Jpn. J. Cancer Res.* 1998; **89**: 385–91.

27 Yamamoto M, Furihata C, Ogiu T *et al*. Independent variation in susceptibilities of six different mouse strains to induction of pepsinogen-altered pyloric glands and gastric tumor intestinalization by N-methyl-N-nitrosourea. *Cancer Lett.* 2002; **179**: 121–32.

28 Leung W, Wu K, Wong C *et al*. Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. *Carcinogenesis* 2008; **29**: 1648–54.

29 Yamamoto M, Tsukamoto T, Sakai H *et al*. p53 knockout mice (−/−) are more susceptible than (+/−) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis. *Carcinogenesis* 2000; **21**: 1891–7.

30 Sakamoto K, Hikiba Y, Nakagawa H *et al*. Inhibitor of kappaB kinase beta regulates gastric carcinogenesis via interleukin-1alpha expression. *Gastroenterology* 2010; **139**: 226–38.

31 Shibata W, Maeda S, Hikiba Y *et al*. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. *Cancer Res.* 2008; **68**: 5031–9.

32 Takasu S, Tsukamoto T, Cao X *et al*. Roles of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression and beta-catenin activation in gastric carcinogenesis in N-methyl-N-nitrosourea-treated K19-C2mE transgenic mice. *Cancer Sci.* 2008; **99**: 2356–64.

33 Ito K, CHuang L, Ito T, Chang T, Fukamachi H, Salto-Tellez M. Loss of Runx3 is a key event in inducing precancerous state of the stomach. *Gastroenterology* 2011; **140**: 1536–46.

34 Humar B, Blair V, Charlton A, More H, Martin I, Guilford P. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. *Cancer Res.* 2009; **69**: 2010–56.

35 Li Q, Jia Z, Wang L *et al*. Disruption of Klf4 in villin-positive gastric progenitor cells promotes formation and progression of tumors in the antrum of mice. *Gastroenterology* 2012; **142**: 531–42.

36 Boffa L, Bolognesi C. Methylating agents: their target amino acids in nuclear proteins. *Carcinogenesis* 1985; **6**: 1399–401.

37 Tomita H, Takaishi S, Menheniott T *et al*. Inhibition of gastric carcinogenesis by the hormone gastrin is mediated by suppression of TFF1 epigenetic silencing. *Gastroenterology* 2011; **140**: 879–91.

38 Wang F, Meng W, Wang B, Qiao L. *Helicobacter pylori*-induced gastric inflammation and gastric cancer. *Cancer Lett.* 2014; **345**: 196–202.

39 Herrera V, Parsonnet J. *Helicobacter pylori* and gastric adenocarcinoma. *Clin. Microbiol. Infect.* 2009; **15**: 971–6.

40 Uemura N, Okamoto S, Yamamoto S *et al. Helicobacter pylori* infection and the development of gastric cancer. *N. Engl. J. Med.* 2001; **345**: 784–9.

41 Polk D, Peek R. *Helicobacter pylori*: gastric cancer and beyond. *Nat. Rev. Cancer* 2010; **10**: 403–14.

42 Azuma T. *Helicobacter pylori* CagA protein variation associated with gastric cancer in Asia. *J. Gastroenterol.* 2004; **39**: 97–103.

43 Yuzhalin A. The role of interleukin DNA polymorphisms in gastric cancer. *Hum. Immunol.* 2011; **72**: 1128–36.

44 Hamajima N, Naito N, Kondo T, Goto Y. Genetic factors involved in the development of *Helicobacter pylori*-related cancer. *Cancer Sci.* 2006; **97**: 1129–38.

45 Kimura R, Nishioka T, Soemantri A, Ishida T. Cis-acting effect of the IL1B C-31T polymorphism on IL-1 beta mRNA expression. *Genes Immun.* 2004; **5**: 572–5.

46 Rad R, Dossumbekova A, Neu B *et al.* Cytokine gene polymophisms influence mucosal cytokine expression, gastric inflammation and host specific colonisation during *Helicobacter pylori* infection. *Gut* 2004; **53**: 1082–1089.

47 Yang J, Hu Z, Xu Y *et al.* Interleukin-1B gene promoter variants are associated with an increased risk of gastric cancer in a Chinese population. *Cancer Lett.* 2004; **215**: 191–8.

48 Palli D, Saieva C, Luzzi I *et al.* Interleukin-1 gene polymorphisms and gastric cancer risk in a high-risk Italian population. *Am. J. Gastroenterol.* 2005; **1000**: 1941–8.

49 Kamangar F, Cheng C, Abnet C, Rabkin C. Interleukin-1B polymorphisms and gastric cancer risk—a meta analysis. *Cancer Epidemiol. Biomarkers Prev.* 2006; **15**: 1920–8.

50 Persson C, Canedo P, Machado J, El-Omar E, Forman D. Polymorphisms in inflammatory response genes and their association with gastric cancer: a HuGE systemic review and meta-analyses. *Am. J. Epidemiol.* 2010; **173**: 259–70.

51 Ehlers S, Warrelmann M, Hahn H. In research of an animal model for experimental *Campylobacter pylori* infection: administration of *Campylobacter* to rodents. *Zentralbl Bakteriol Mikrobiol Hyg A.* 1988; **268**: 341–6.

52 Cantona M, Balish E. Inability of human clinical strains of *Helicobacter pylori* to colonize the alimentary tract of germfree rodents. *Can. J. Microbiol.* 1990; **36**: 237–41.

53 Lee A, Fox J, Otto G, Murphy J. A small animal model of human *Helicobacter pylori* active chronic gastritis. *Gastroenterology* 1990; **99**: 1315–23.

54 Fox J, Sheppard B, Dangler C, Whary M, Ihrig M, Wang T. Germ-line p53 targeted disruption inhibits *Helicobacter*-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 pro-inflammatory responses. *Cancer Res.* 2002; **62**: 696–702.

55 Houghton J, Wang T. *Helicobacter pylori* and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. *Gastroenterology* 2005; **128**: 1567–78.

56 Lee A, CHen M, Coltro N *et al.* Long term infection of the gastric mucosa with *Helicobacter* species does induce atrophic gastritis in an animal model of *Helicobacter pylori* infection. *Zentralbl Bakteriol.* 1993; **280**: 38–50.

57 Stoicov C, Saffari R, Cai X, Hasyagar C, Houghton J. Molecular biology of gastric cancer: *Helicobacter* infection and gastric adenocarcinoma—bacterial and host factors responsible for altered growth signaling. *Gene* 2004; **341**: 1–17.

58 Lee C, Rickman B, Rogers A, Ge Z, Wang T, Fox J. *Helicobacter pylori* eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. *Cancer Res.* 2008; **68**: 3540–8.

59 Ley C, Mohar A, Guarner J *et al. Helicobacter pylori* eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. *Cancer Epidemiol. Biomarkers Prev.* 2004; **13**: 4–10.

60 Lee A, O'Rourke J, Ungria M, Robertson B, Daskalopoulos G, Dixon M. A standardized mouse model of *Helicobacter pylori* infection: introducing the Sydney strain. *Gastroenterology* 1997; **112**: 1386–97.

61 Wang X, Willen R, Svensson M, Ljungh A, Wadstrom T. Two-year follow-up of *Helicobacter pylori* infection in C57BL/6 and Balb/cA mice. *Acta Pathol. Microbiol. Immunol. Scand.* 2003; **111**: 512–22.

62 Greenfield L, Jones N. Modulation of autophagy by *Helicobacter pylori* and its role in gastric carcinogenesis. *Trends Microbiol.* 2013; **21**: 602–12.

63 Maeda S, Yoshida H, Ogura K *et al. H. pylori* activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2 and TRAF6 in gastric cancer cells. *Gastroenterology* 2000; **119**: 97–108.

64 Mitsuno Y, Yoshida H, Maeda S *et al. Helicobacter pylori* induced transactivation of SRE and AP-1 through the ERK signalling pathway in gastric cancer cells. *Gut* 2001; **49**: 18–22.

65 Arnold I, Lee J, Amieva M *et al.* Tolerance rather than immunity protects from *Helicobacter pylori*-induced gastric preneoplasia. *Gastroenterology* 2011; **140**: 199–209.

66 Beckler A, Roche J, Harper J *et al.* Decreased abundance of trefoil factor 1 transcript in the majority of gastric carcinomas. *Cancer* 2003; **98**: 2184–91.

67 Fujimoto J, Yasui W, Tahara H, Tahara E, Kudo Y, Yokozaki H. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis. *Cancer Lett.* 2000; **149**: 125–34.

68 Peterson A, Menheniott T, O'Connor L *et al. Helicobacter pylori* infection promotes methylation and silencing of Trefoil Fator 2, leading toe gastric tumour development in mice and humans. *Gastroenterology* 2010; **139**: 2005–17.

69 Clyne M, Dillon P, Daly S *et al. Helicobacter pylori* interacts with the human single domain trefoil protein TFF1. *Proc. Natl. Acad. Sci. U. S. A.* 2008; **101**: 7409–14.

70 Reeves E, Ali T, Leonard P *et al. Helicobater pylori* lipopolysaccharide interacts with TFF1 in a pH-dependent manner. *Gastroenterology* 2008; **135**: 2043–53.

71 Soutto M, Romero-Gallo J, Krishna3 U *et al.* Loss of TFF1 promotes *Helicobacter pylori*-induced β-catenin activation and gastric tumorigenesis. *Oncotarget.* 2015; **6**(20): 17911–22.

72 Wang T, Goldenring J, Dangler C *et al.* Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with *Helicobacter felis* infection. *Gastroenterology* 1998; **114**: 675–89.

73 Ismail H, Fick P, Zhang J, Lynch R, Berg D. Depletion of neutrophils in IL-10(−/−) mice delays clearance of gastric *Helicobacter* infection and decreases Th1 immune response to *Helicobacter*. *J. Immunol.* 2003; **170**: 3782–9.

74 Smythies L, Waites K, Lindsey J, Harris P, Ghiara P, Smith P. *Helicobacter pylori*-induced inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene deficient mice. *J. Immunol.* 2000; **165**: 1022–9.

75 Fox J, Rogers A, Ihrig M *et al. Helicobacter pylori*-associated gastric cancer in INS-GAS mice is gender specific. *Cancer Res.* 2003; **63**: 942–50.

76 Toyoda T, Tsukamoto T, Tamamoto M *et al.* Gene expression analysis of a *Helicobacter pylori*-infected and high-salt diet-treated mouse gastric tumor model: identification of CD177 as a novel prognostic factor in patients with gastric cancer. *BMC Gastroenterol.* 2013; **13**: 1–11.

77 Lofgren J, Whary M, Ge Z *et al*. Lack of commensal flora in *Helicobacter pylori*-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. *Gastroenterology* 2011; **140**: 210–20.

78 Chen D, Stenström B, Zhao C-M, Wadström T. Does *Helicobacter pylori* infection *per se* cause gastric cancer or duodenal ulcer? Inadequate evidence in Mongolian gerbils and inbred mice. *FEBS Immunol. Med. Biol.* 2007; **50**: 184–9.

79 Marostica M, Arcari D, Bartchewsky W *et al*. Effects of a one-week treatment with acid gastric inhibitors on *Helicobacter pylori*-infected mice. *Scand. J. Gastroenterol.* 2007; **42**: 1404–12.

80 Hahm K, Song Y, Oh E *et al*. Chemo-prevention of *Helicobacter pylori*-associated carcinogenesis in a mouse model: is it possible? *J. Bichem. Mol. Biol.* 2003; **36**: 82–94.

81 Zhang S, Lee S, Morrissey R, Aponte-Pieras J, Rogers A, Moss S. Early or late antibiotic intervention prevents *Helicobacter pylori*-induced gastric cancer in a mouse model. *Cancer Lett.* 2014; **355**: 106–12.

82 Hilleringmann M, Pansegrau W, Doyle M *et al*. Inhibitors of *Helicobacter pylori* ATPase Caga block CagA transport and cag virulence. *Microbiology* 2006; **152**: 2919–30.

83 Aristoteli L, O'Rourke J, Danon S *et al*. Urea, fluorofamide and omeprazole treatments alter *Helicobacter* colonization in the mouse gastric mucosa. *Helicobacter* 2006; **11**: 460–8.

84 Gavrish E, Shrestha B, Chen C *et al In vitro* and *in vivo* activities of HPi1, a selective antimicrobial against *Helicobacter pylori*. *Antimicrob. Agents Chemother.* 2014; **58**: 3255–60.

85 Shin J, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: structure, function and inhibition. *Pflugers Arch.* 2009; **457**: 609–22.

86 Karam S, Forte J. Inhibiting gastric H(+)-K(+)-ATPase activity by omeprazole promotes degeneration and production of parietal cells. *Am. J. Physiol.* 1994; **266**: G7745–58.

87 Li Q, Karam S, Gordon J. Simian virus 40 T antigen-induced amplification of pre-parietal cells in transgenic mice. Effects on other gastric epithelial cell lineages and evidence for a p53-independent apoptotic mechanism that operates in a committed progenitor. *J. Biol. Chem.* 1995; **270**: 15777–88.

88 Spicer Z, Miller M, Angringa A *et al*. Stomachs of mice lacking the gastric H,K-ATPase alpha-subunit have achlorhydria, abnormal parietal cells and ciliated metaplasia. *J. Biol. Chem.* 2000; **275**: 21555–65.

89 Judd L, Andringa A, Rubio C, Spicer Z, Schull G, Miller M. Gastric achlorhydria in H/K-ATPase-deficient (Atp4a(−/−)) mice causes severe hyperplasia, mucocystic metaplasia and upregulation of growth factors. *J. Gastroenterol. Hepatol.* 2005; **20**: 1266–78.

90 Scarff K, Judd L, Toh B, Gleeson P, Driel IV. Gastric H(+), K(+)-adenosine triphosphatase beta subunit is required for normal function, development, and membrane structure of mouse parietal cells. *Gastroenterology* 1999; **117**: 605–19.

91 Gut M, Vernerova SP, Rohde R *et al*. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. *Gastroenterology* 2002; **123**: 1889–903.

92 Silberg D, Sullivan J, Kang E *et al*. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. *Gastroenterology* 2002; **122**: 689–96.

93 Mutoh H, Hakamata Y, Sato K *et al*. Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice Biochemical and Biophysical Research. *Commun.* 2002; **294**: 470–9.

94 Silberg D, Furth E, Taylor J, Schuck T, Chiou T, Traber P. CDX1 protein expression in normal, metaplasia, and neoplastic human alimentary tract epithelium. *Gastroenterology* 1997; **113**: 478–86.

95 Mutoh H, Sakurai S, Satoh S *et al*. Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice. *Gut* 2004; **53**: 1416–23.

96 Coffey RJ, Washington MK, Corless CL, Heinrich MC. Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. *J. Clin. Invest.* 2007; **117**: 70–80.

97 Takagi H, Fukusato T, Kawaharada U, Kuboyama S, Merlino G, Tsutsumi Y. Histochemical analysis of hyperplastic stomach of TGF-alpha transgenic mice. *Dig. Dis. Sci.* 1997; **42**: 91–8.

98 Goldenring J, Ray G, Soroka C *et al*. Overexpression of transforming growth factor-alpha alters differentiation of gastric cell lineages. *Dig. Dis. Sci.* 1996; **41**: 773–84.

99 Dahlhoff M, Gerhard M, Rad R, Linden S, Wolf E, Schneider M. A new mouse model for studying EGFR-dependent gastric polyps. *Biochem Biophys Acta.* 2012; **1822**: 1293–9.

100 Goldenring J, Ray G, Coffey R *et al*. Reversible drug-induced oxyntic atrophy in rats. *Gastroenterology* 2000; **118**: 1080–93.

101 Nomura S, Yamaguchi H, Ogawa M, Wang T, Lee J, Goldenring J. Alterations in gastric mucosal lineages induced by acute oxyntic atrophy in wild-type and gastrin-deficient mice. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2005; **288**: G362–75.

102 Ogawa M, Nomura S, Varro A, Wang T, Goldenring J. Altered metaplastic response of waved-2 EGF receptor mutant mice to acute oxyntic atrophy. *Am. J. Physiol.* 2006; **290**: G793–804.

103 Nam K, Varro A, Coffey R, Goldenring J. Potentiation of oxyntic atrophy-induced gastric metaplasia in amphiregulin-deficient mice. *Gastroenterology* 2007; **132**: 1804–19.

104 Ferrand A, Wang T. Gastrin and cancer. *Cancer Lett.* 2006; **238**: 15–29.

105 Koh T, Goldenring J, Ito S *et al*. Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice. *Gastroenterology* 1997; **113**: 1015–25.

106 Wang T, Brand S. Function and regulation of gastrin in transgenic mice: a review. *Yale J. Biol. Med.* 1992; **65**: 705–40.

107 Wang T, Dangler C, Chen D *et al*. Synergistic interaction between hypergastrinemia and *Helicobacter* infection in a mouse model of gastric cancer. *Gastroenterology* 2000; **118**: 36–47.

108 Fox J, Wang T, Rogers A *et al*. Host and microbial constituents influence *Helicobacter pylori*-induced cancer in a murine model of hypergastrinemia. *Gastroenterology* 2003; **124**: 1879–90.

109 Ohtani M, Garcia A, Rogers A *et al*. Protective role of 17 beta-estradiol against the development of *Helicobacter pylori*-induced gastric cancer in INS-GAS mice. *Carcinogenesis* 2007; **28**: 2597–604.

110 Takaishi S, Tu S, Dubeykovskaya ZA *et al*. Gastrin is an essential cofactor for *Helicobacter*-associated gastric corpus carcinogenesis in C57BL/6 mice. *Am. J. Pathol.* 2009; **175**: 365–75.

111 Takaishi S, Wang T. Gene expression profiling in a mouse model of *Helicobacter*-induced gastric cancer. *Cancer Sci.* 2007; **98**: 284–93.

112 Lee C-W, Rickman B, Rogers A *et al*. Combination of Sulindac and the antimicrobial eradication of *Helicobacter pylori* prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. *Cancer Res.* 2009; **69**: 8166–74.

113 Takaishi S, Cui G, Frederick D *et al*. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on *Helicobacter*-induced gastric cancer. *Gastroenterology* 2005; **128**: 1695–983.

114 Zavros Y, Rieder G, Ferguson A, Samuelson L, Merchant J. Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. *Gastroenterology* 2002; **122**: 119–33.

115 Friis-Hansen L, Rieneck K, Nilsson H, Wadstrom T, Rehfeld J. Gastric inflammation, metaplasia and tumor development in gastrin-deficient mice. *Gastroenterology* 2006; **131**: 256–8.

116 Schlag P, Bockler P, Peter M. Nitrite and nitrosamines in gastric juice: risk factors for gastric cancer? *Scand. J. Gastroenterol.* 1982; **17**: 145–50.

117 Faller G, Dimmler A, Rau T *et al*. Evidence for acid-induced loss of Cdx2 expression in duodenal gastric metaplasia. *J. Pathol.* 2004; **203**: 904–8.

118 El-Omar E, Carrington M, Chow W *et al*. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 2000; **404**: 398–402.

119 Tu S, Bhagat G, Cui G *et al*. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. *Cancer Cell* 2008; **12**: 408–19.

120 Song X, Krelin Y, Dvorkin T *et al*. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumours of IL-1beta secreting cells. *J. Immunol.* 2005; **175**: 8200–8.

121 Waghray M, Zvros Y, Saqui-Salces M *et al*. Interleukin-1beta promotes gastric atrophy through suppression of Sonic hedgehog. *Gastroenterology* 2010; **138**: 562–72.

122 Quante M, Tu SP, Tomita H *et al*. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. *Cancer Cell* 2011; **19**: 257–72.

123 Tatematsu M, Yamamoto M, Iwata H *et al*. Induction of glandular stomach cancers in C3H mice treated with N-Methyl-N-Nitrosourea in the drinking water. *Jpn. J. Cancer Res.* 1993; **84**: 1258–64.

124 Bromberg J, Wrzeszczynska M, Devgan G *et al*. Stat3 as an oncogene. *Cell* 1999; **98**: 295–303.

125 Bollrath J, Phesse T, Burstin V *et al*. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumourigenesis. *Cell* 2009; **15**: 91–102.

126 Ernst M, Najovska M, Grail D *et al*. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumour. *J. Clin. Invest.* 2008; **118**: 1727–8.

127 Putoczki T, Thiem S, Loving A, Busuttil R, Wilson N, Ziegler P. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumourigenesis and can be targeted therapeutically. *Cancer Cell* 2013; **24**: 257–71.

128 Thiem S, Pierce TP, Palmieri M *et al*. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. *J. Clin. Invest.* 2013; **123**: 767–80.

129 Judd L, Alderman B, Howlett M, Shilkes A, Dow C, Moverly J. Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. *Gastroenterology* 2004; **126**: 197–207.

130 Jenkins B, Grail D, Nheu T, Nakdovska M, Wang B, Waring P. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signalling. *Nat. Med.* 2005; **11**: 845–52.

131 Tye H, Kennedy C, Najdovska M *et al*. STAT3-driven upregulation of TLR2 promotes gastric tumourigenesis independent of tumor inflammation. *Cancer Cell* 2012; **22**: 466–78.

132 Uno K, Kato K, Atsumi T *et al*. Toll-like receptor (TLR)2 induced through TLR4 signaling initiated by *Helicobacter pylori* cooperatively amplifies iNOS2 induction in gastric epithelial cells. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2007; **293**: G1004–G12.

133 Tahara T, Arisawa T, Wang F *et al*. Toll-like receptor 2 −196 to 174 del polymorphism influences the susceptibility of Japanese people to gastric cancer. *Cancer Sci.* 2007; **98**: 1790–4.

134 Hold G, Rabkin C, Chow W *et al*. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric cancer and its precursors. *Gastroenterology* 2007; **132**: 905–12.

135 Kennedy C, Najdovska M, Tye H *et al*. Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis. *Oncogene* 2014; **33**: 2540–6.

136 Mistrya P, Lairda MHW, Schwarza RS *et al*. Inhibition of TLR2 signaling by small molecule inhibitors targeting a pocket within the TLR2 TIR domain. *Proc. Natl. Acad. Sci. U. S. A.* 2015; **112**: 5455–60.

137 Zhou S, Cerny A, Bowen G *et al*. Discovery of a novel TLR2 signaling inhibitor with anti-viral activity. *Antiviral Res.* 2010; **87**: 295–306.

138 Heinrich P, Behrmann I, Haan S, Hermanns H, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. *Biochem. J.* 2003; **374**: 1–20.

139 Stuart E, Buchert M, Putoczki T *et al*. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice. *Mol. Cancer Ther.* 2014; **13**: 468–74.

140 Judd L, Menheniott T, Ling H *et al*. Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth *in vitro* and *in vivo*. *PLoS One* 2014; **9**: 1–9.

141 Sonbol M, Firwana B, Zarzour A, Morad M, Rana V, Tiu R. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. *Ther. Adv. Hematol.* 2013; **4**: 15–35.

142 Jancik S, Drabek J, Radzioch D, Hajduch M. Clinical relevance of KRAS in human cancers. *J. Biomed. Biotechnol.* 2010; **2010**: 1–13.

143 Okumura T, Ericksen R, Taishi S *et al*. K-ras mutation targeted to gastric tissue progenitor cells results in chronic inflammation, an altered microenvironment, and progression to intraepithelial neoplasia. *Cancer Res.* 2010; **70**: 8435–45.

144 Ray K, Bell K, Yan J *et al*. Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. *PLoS One* 2011; **6**: e16786.

145 Matkar S, Durham A, Brice A, Wang T, Rustgi A, Hua X. Systemic activation of K-ras rapidly induces gastric hyperplasia and metaplasia in mice. *Am. J. Cancer Res.* 2011; **1**: 432–45.

146 Bossenmeyer-Pourie C, Kannan R, Ribieras S, Wendling C, Stoll I, Thim L. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. *J. Cell Biol.* 2002; **157**: 761–70.

147 Tomasetto S, Masson R, Linares J, Wendling C, Lefebvre O, Chenard M. ps2/TFF1 interacts directly with the VWFC cysteine-rich domains of mucins. *Gastroenterology* 2000; **118**: 70–80.

148 Rio M, Chenard M, Wolf C, Marcellin L, TOmasetto C, Lathe R. Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract. *Gastroenterology* 1991; **100**: 375–9.

149 Kjellev S. The trefoil factor family—small peptides with multiple functionalities. *Cell. Mol. Life Sci.* 2009; **66**: 1350–69.

150 Playford R, Marchbank T, Goddlad R, Chinery R, Poulsom R, Hanby A. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. *Proc. Natl. Acad. Sci. U. S. A.* 1996; **93**: 2137–42.

151 Lefebvre O, Chenard M, Masson R *et al*. Gastric mucosa abnormalities and tumourigenesis in mice lacking the pS2 trefoil protein. *Science* 1996; **274**: 259–62.

152 Soutto M, Belkhiri A, Piazuelo M *et al*. Loss of TFF is associated with activation of NF-kB-mediated inflammation and gastric neoplasia in mice and humans. *J. Clin. Invest.* 2011; **121**: 1753–67.

153 Saukkonen K, Tomasetto C, Narko K, Rio M, Ristimaki A. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. *Cancer Res.* 2003; **63**: 3032–6.

154 Mrena J, Wiksten J, Thiel A *et al*. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. *Clin. Cancer Res.* 2005; **11**: 7362–8.

155 Rees B, Saukkonen K, Ristimaki A *et al*. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. *J. Pathol.* 2002; **196**: 171–9.

156 Saukkonen K, Nieminen O, Rees V *et al*. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. *Clin. Cancer Res.* 2001; **7**: 1923–31.

157 Thiel A, Narko K, Heinonen M *et al*. Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. *Int. J. Cancer* 2012; **131**: 1032–41.

158 Sakamoto H, Yoshimura K, Saeki N *et al*. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. *Nat. Genet.* 2008; **40**: 730–40.

159 Abnet C, Freedman N, Hu N *et al*. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. *Nat. Genet.* 2010; **42**: 764–7.

160 Thiem S, Eissmann MF, Elzer J, Jonas A *et al*. Stomach-specific activation of oncogenic KRAS and STAT3-dependent inflammation cooperatively promote gastric tumorigenesis in a preclinical model. *Cancer Res.* 2016; [Epub ahead of print].

161 Holmlund C, Nilsson J, Guo D *et al*. Characterization and tissue-specific expression of human LRIG2. *Gene* 2004; **12**: 35–43.

162 Nam K, Lee H, Sousa J *et al*. Mature chief cells are cryptic progenitors for metaplasia in the stomach. *Gastroenterology* 2010; **139**: 2028–37.

163 Quante M, Marrache F, Goldenring J, Wang T. TFF2 mRNA transcript expression markers a gland progenitor cell of the gastric oxyntic mucosa. *Gastroenterology* 2010; **139**: 2018–27.e2.

164 Hahm K, Lee K, Kim Y *et al*. Conditional loss of TGF-beta signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. *Aliment. Pharmacol. Ther.* 2002; **16**: 115–27.

165 Tatematsu M, Ogawa K, Hoshiya T, Shichino Y, Kato T, Imaida K. Induction of adenocarcinomas in the glandular stomach of BALB/c mice treated with N-methyl-N-nitrosourea. *Jpn. J. Cancer Res.* 1992; **83**: 915–8.

166 Nakamura Y, Sakagami T, Yamamoto N *et al*. *Helicobacter pylori* does not promote N-Methyl-N-nitrosourea-induced gastric carcinogenesis in SPF C57BL/6 mice. *Jpn. J. Cancer Res.* 2002; **93**: 111–6.

167 Han S, Kim Y, Koo H *et al*. Helicobater pylori infection promotes gastric carcinogenesis in a mice model. *J. Gastroenterol. Hepatol.* 2002; **17**: 253–61.

168 Nagata A, Ito M, Iwata N *et al*. G protein-coupled cholecystokinin-B/gastric receptors are responsible for physiological cell growth of the stomach mucosa *in vivo*. *Proc. Natl. Acad. Sci. U. S. A.* 1996; **93**: 11825–30.

169 Nomura S, Settle S, Leys C *et al*. Evidence for repatterning of the gastric fundic epithelial associated with Menetrier's disease and TGFalpha overexpression. *Gastroenterology* 2005; **128**: 1292–305.

170 Franic T, Judd L, Robinson D *et al*. Regulation of gastric epithelial cell development revleaed in H(+)/K(+)-ATPase beta-subunit and gastrin-deficient mice. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2001; **281**: G1502–11.

171 Syu S, El-aatari M, Eaton K *et al*. Transgenic expression of Interferon-y in mouse stomach leads to inflammation, metaplasia and dysplasia. *Am. J. Pathol.* 2012; **181**: 2114–25.

172 Xiao C, Ogle S, Schumacher M *et al*. Loss of parietal cell expression of Sonic hedgehog induces hypergastrinemia and hyperproliferation of surface mucous cells. *Gastroenterology* 2010; **138**: 550–61.

173 Nam K, Lee H, Sousa J *et al*. Mature chief cells are cryptic progenitors for metaplasia in the stomach. *Gastroenterology* 2010; **129**: 2028–37.

174 Schultheis P, Clarke L, Meneton P *et al*. Targeted disruption of the murine Na/H+ exchanger isoform 2 gene causes reduced viability of gastric parietal cells and loss of net acid secretion. *J. Clin. Invest.* 1998; **101**: 1243–53.

175 Kanda N, Seno H, Kawada M *et al*. Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice. *Am. J. Physiol.* 2006; **290**: G519–G27.

176 Andersson P, McGuire J, Rubio C *et al*. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. *Proc. Natl. Acad. Sci. U. S. A.* 2002; **99**: 9990–5.

177 Thompson J, Epting T, Schwarzkopf G *et al*. A transgenic mouse line that develops early-onset invasive gastric carcinoma provides a model for carcinoembryonic antigen-targeted tumor therapy. *Int. J. Cancer* 2000; **86**: 863–9.

178 Shimada S, Mimata A, Sekine M *et al*. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. *Gut* 2012; **61**: 344–53.

179 Mutoh H, Sakurai S, Satoh K *et al*. Development of gastric carcinoma from intestinal metaplasia in Cdx2-transgenic mice. *Cancer Res.* 2004; **64**: 7740–7.

180 Hahn J, Falck V, Jirik F. Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice. *J. Clin. Invest.* 2011; **121**: 4030–42.

181 Barker N, Huch M, Kujala P *et al*. Lgr5+ve stem cells drive self-renewal in the stomach and build long-lived gastric units *in vitro*. *Cell Stem Cell* 2010; **6**: 25–36.

182 Koike K, Hinrichs S, Isselbacher K, Jay G. Transgenic mouse model for human gastric carcinoma. *Proc. Natl. Acad. Sci. U. S. A.* 1989; **86**: 5615–9.

183 Tsuzuki T, Egashira A, Igarashi H *et al*. Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase. *Proc. Natl. Acad. Sci. U. S. A.* 2001; **25**: 11456–61.

184 Nam KT, O'Neal R, Lee YS, Lee YC, Coffey RJ, Goldenring JR. Gastric tumor development in Smad3-deficient mice initiates from forestomach/glandular transition zone along the lesser curvature. *Lab. Invest.* 2012; **92**: 883–95.

185 Takaku K, Miyoshi H, Matsunaga A, Oshima M, Sasaki N, Taketo M. Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. *Cancer Res.* 1999; **59**: 6113–7.

186 Oshima H, Matsunaga A, Fujimura T, Tsukamoto T, Taketo M, Oshima M. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. *Gastroenterology* 2006; **131**: 1086–95.